A useful testing strategy in phase III trials: combined test of superiority and test of equivalence.

Abstract:

:A useful testing strategy is proposed for a confirmatory phase III clinical trial. It consists of a combined test of superiority and test of equivalence, and it is easy to apply. By introducing the strategy, we can perform a post hoc analysis in a confirmatory experiment. Thus a more flexible decision will be possible than the usual single testing method provides. It is shown that the procedure needs no adjustment for multiplicity from the point of view of the closed testing procedure. The relationship between this strategy and a confidence interval is also discussed.

journal_name

J Biopharm Stat

authors

Morikawa T,Yoshida M

doi

10.1080/10543409508835115

subject

Has Abstract

pub_date

1995-11-01 00:00:00

pages

297-306

issue

3

eissn

1054-3406

issn

1520-5711

journal_volume

5

pub_type

杂志文章
  • An adaptive two-stage dose-response design method for establishing proof of concept.

    abstract::We propose an adaptive two-stage dose-response design where a prespecified adaptation rule is used to add and/or drop treatment arms between the stages. We extend the multiple comparison procedures-modeling (MCP-Mod) approach into a two-stage design. In each stage, we use the same set of candidate dose-response models...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.813519

    authors: Franchetti Y,Anderson SJ,Sampson AR

    更新日期:2013-01-01 00:00:00

  • Selecting combinations of chemotherapeutic drugs to maximize dose intensity.

    abstract::A mathematical model is described for selecting combinations of chemotherapeutic drugs in order to maximize antitumor dose intensity subject to constraints on toxicity to normal organ systems. Determination of which drugs to combine and in what proportions to combine them offers combinatorially huge numbers of possibi...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409108835022

    authors: Simon R,Korn EL

    更新日期:1991-01-01 00:00:00

  • Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.

    abstract::To confirm results obtained from local evaluation at investigational centers, many oncology studies utilize blinded independent central review (BICR) to make assessments of the primary endpoint, progression-free survival (PFS). The comparison of data often leads to large discordances between these observations, castin...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.813516

    authors: Mannino FV,Amit O,Lahiri S

    更新日期:2013-01-01 00:00:00

  • Symmetry in square contingency tables: tests of hypotheses and confidence interval construction.

    abstract::Bowker's test, a generalization of McNemar's test, performs well under the hypothesis of symmetry, but the estimator of variance used in the test is biased when the table is asymmetric and this calls into question the test's performance in non-null situations. We seek an alternative to Bowker's test in search of metho...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100104195

    authors: May WL,Johnson WD

    更新日期:2001-02-01 00:00:00

  • Alternative approaches to the analysis of binary and categorical repeated measurements.

    abstract::The purpose of this paper is to describe, illustrate, and compare a number of different approaches to the analysis of repeated binary and categorical data. These approaches include empirical generalized least squares and generalized estimating equations, as well as traditional log-linear modeling methods. It is shown ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409208835036

    authors: Kenward MG,Jones B

    更新日期:1992-01-01 00:00:00

  • Robust small-sample inference for fixed effects in general Gaussian linear models.

    abstract::Although asymptotically, the empirical covariance estimator is consistent and robust with respect to the selection of the working correlation matrix, when the sample size is small, its bias may not be negligible. This article proposes a small sample correction for the empirical covariance estimator in general Gaussian...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.557792

    authors: Fan C,Zhang D,Zhang CH

    更新日期:2012-01-01 00:00:00

  • Design and sample size considerations for simultaneous global drug development program.

    abstract::Due to the potential impact of ethnic factors on clinical outcomes, the global registration of a new treatment is challenging. China and Japan often require local trials in addition to a multiregional clinical trial (MRCT) to support the efficacy and safety claim of the treatment. The impact of ethnic factors on the t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2012.701587

    authors: Huang Q,Chen G,Yuan Z,Lan KK

    更新日期:2012-09-01 00:00:00

  • Dose finding with the sequential parallel comparison design.

    abstract::The sequential parallel comparison design (SPCD) is a two-stage design recommended for trials with possibly high placebo response. A drug-placebo comparison in the first stage is followed in the second stage by placebo nonresponders being re-randomized between drug and placebo. We describe how SPCD can be used in tria...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.924960

    authors: Wang JJ,Ivanova A

    更新日期:2014-01-01 00:00:00

  • A comparison of test procedures for multidose animal carcinogenicity assays under competing risks.

    abstract::Four multidose animal carcinogenicity assay trend test procedures based on the chi-square, Hoel-Walburg, log-rank, and Peto procedures are compared under conditions of competing risks. A total of 42 different risk populations are simulated in which a simulated animal can contract one or more of five different tumor ty...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409408835089

    authors: Graves TS

    更新日期:1994-11-01 00:00:00

  • Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.

    abstract::The design of a three-arm trial including the experimental treatment, an active reference treatment, and a placebo is recommended as a useful approach to the assessment of noninferiority of the experimental treatment. The inclusion of the placebo arm enables the assessment of assay sensitivity and internal validation,...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.789893

    authors: Hida E,Tango T

    更新日期:2013-01-01 00:00:00

  • Testing gene-treatment interactions in pharmacogenetic studies.

    abstract::Drug-related side effects are one of the leading causes of death and illness in the developed world. Finding genes that modify drug response has the potential to significantly improve drug delivery, by identifying both individuals that can benefit from therapy and those at increased risk of harm. We present a simple a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903572761

    authors: He M,Allen A

    更新日期:2010-03-01 00:00:00

  • Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial.

    abstract::ETRANK is a statistical software which uses nonparametric (randomization) technique to analyze incomplete repeated measures data, where the pattern of withdrawal is treatment related. This stand alone program is written in C, presently runs in MS-DOS, and a Windows version is in development. The program has been devel...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409608835156

    authors: Entsuah R

    更新日期:1996-11-01 00:00:00

  • Balancing statistical and ethical considerations in planning clinical trials: recommendations for response-adaptive randomization urn designs.

    abstract::During a clinical trial, balancing statistical and ethical considerations are important. Response-adaptive randomization methods use the information from past patients to increase the probability of the next patient receiving the better treatment while avoiding the statistical concern of selection bias. We compared th...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2018.1437172

    authors: Piccorelli AV,Fraker SA

    更新日期:2018-01-01 00:00:00

  • Bayesian approach to evaluation of bridging studies.

    abstract::We address the issue of analysis of clinical data generated by the bridging study conducted in the new region to evaluate the similarity for extrapolation of the foreign clinical data. A bridging study is usually conducted in the new region only after the test product is approved for commercial marketing in the origin...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-120014568

    authors: Liu JP,Hsiao CF,Hsueh H

    更新日期:2002-08-01 00:00:00

  • Bayesian approach for cure models with a change-point based on covariate threshold: application to breast cancer data.

    abstract::In this study, a Bayesian approach was suggested to estimate a change-point according to a covariate threshold when some patients never experienced the event of interest. Gibbs sampler algorithm with latent binary cure indicators was used to simplify the implementation of Markov chain Monte Carlo method. Then, the acc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1632877

    authors: Shamsi F,Baghestani AR,Binesh F

    更新日期:2020-03-01 00:00:00

  • On sample size determination in multi-armed confirmatory adaptive designs.

    abstract::An important application of confirmatory adaptive designs is the data-driven selection of treatment arms in multi-armed trials. A general methodology for adaptive designs is based on the combination testing principle. Using this principle, selection of treatment arms in multi-armed designs, recalculation of sample siz...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.551336

    authors: Wassmer G

    更新日期:2011-07-01 00:00:00

  • Equivalence tests for shelf life and average drug content in stability studies.

    abstract::Stability testing is a procedure frequently used in the pharmaceutical industry to estimate the shelf life of a drug. Hereby, a standard problem of interest is whether or not to pool a given number of batches to assign a single shelf life for the combined batches. In this paper, we propose two modified methods for the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802287230

    authors: Djira GD,Hothorn LA,Tsong Y

    更新日期:2008-01-01 00:00:00

  • A group sequential approach to crossover trials for average bioequivalence.

    abstract::Group sequential methods to allow the possibility of early termination of a trial due to sufficiently convincing results are a standard in therapeutic clinical trials but have been little considered in bioequivalence trials. We investigate the statistical properties of one group sequential approach to bioequivalence t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409708835171

    authors: Hauck WW,Preston PE,Bois FY

    更新日期:1997-03-01 00:00:00

  • Ratio of means vs. difference of means as measures of superiority, noninferiority, and average bioequivalence.

    abstract::Ratio of means (ROM) and difference of means (DOM) are often used in a superiority, noninferiority (NI), or average bioequivalence (ABE) test to evaluate whether the test mean is superior, NI, or equivalent to the reference (placebo or active control) mean. The literature provides recommendations regarding how to choo...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265536

    authors: Sun W,Grosser S,Tsong Y

    更新日期:2017-01-01 00:00:00

  • Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.

    abstract::This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.1000546

    authors: Abel UR,Jensen K,Karapanagiotou-Schenkel I,Kieser M

    更新日期:2015-01-01 00:00:00

  • Interval estimation of the proportion ratio in repeated binary measurements under a stratified randomized clinical trial with noncompliance.

    abstract::The proportion ratio (PR) of a positive response between an experimental treatment and a standard treatment (or placebo) is often used to measure the relative treatment efficacy in a randomized clinical trial (RCT). For ethical reasons, it is almost inevitable to encounter some patients not complying with their assign...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.508139

    authors: Lui KJ,Chang KC

    更新日期:2012-01-01 00:00:00

  • Influence Analysis for the Area Under the Receiver Operating Characteristic Curve.

    abstract::Classification measures play essential roles in the assessment and construction of classifiers. Hence, determining how to prevent these measures from being affected by individual observations has become an important problem. In this paper, we propose several indexes based on the influence function and the concept of l...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1377728

    authors: Ke BS,Chiang AJ,Chang YI

    更新日期:2018-01-01 00:00:00

  • Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

    abstract::In this article, a parametric sequential test is proposed under the Weibull model. The proposed test is asymptotically normal with an independent increment structure. The sample size for a fixed sample test is derived for the purpose of group sequential trial design. In addition, a multi-stage group sequential procedu...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.971165

    authors: Wu J,Xiong X

    更新日期:2015-01-01 00:00:00

  • Assessment of antitumor activity for tumor xenograft studies using exponential growth models.

    abstract::In preclinical tumor xenograft experiments, the antitumor activity of the tested agents is often assessed by endpoints such as tumor doubling time, tumor growth delay (TGD), and log10 cell kill (LCK). In tumor xenograft literature, the values of these endpoints are presented without any statistical inference, which ig...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.481802

    authors: Wu J

    更新日期:2011-05-01 00:00:00

  • Analysis of recurrent hypoglycemic events.

    abstract::Hypoglycemia is a major safety concern for diabetic patients. Hypoglycemic events can be modeled based on time to recurrent events or count data. In this article, we evaluated a gamma frailty model with variance estimated by the inverse of observed Fisher information matrix, a gamma frailty model with the sandwich var...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1765370

    authors: Ma C,Qu Y,Fu H

    更新日期:2020-05-18 00:00:00

  • Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.

    abstract::Using multistage adaptive group sequential test designs, the investigator may perform data-driven changes in the design during the course of the trial without inflation of the Type I error rate. This is possible, for example, through the use of the inverse normal method of combining the p-values from the separate stag...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120024196

    authors: Wassmer G

    更新日期:2003-11-01 00:00:00

  • Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

    abstract::A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we prop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1226324

    authors: Li JX,Chen WC,Scott JA

    更新日期:2016-01-01 00:00:00

  • On evaluation of consistency in multi-regional clinical trials.

    abstract::In recent years, multi-regional clinical trials (MRCT) that conduct clinical trials simultaneously in Asian Pacific region, Europe, and the United States have become very popular for global pharmaceutical development. The main purpose of multi-regional clinical trials is to shorten the time for pharmaceutical developm...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1397008

    authors: Ying L,Song F,Chow SC,Zeng N,Zheng J,Li X,Henry D,Sethuraman V

    更新日期:2018-01-01 00:00:00

  • An evaluation of increasing sample size based on conditional power.

    abstract::We evaluate properties of sample size re-estimation (SSR) designs similar to the promising zone design considered by Mehta and Pocock (2011). We evaluate these designs under the assumption of a true effect size of 1.1 down to 0.4 of the protocol-specified effect size by six measures: 1. The probability of a sample siz...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1289943

    authors: Gaffney M,Ware JH

    更新日期:2017-01-01 00:00:00

  • On sample size calculation based on odds ratio in clinical trials.

    abstract::Sample size calculation formulas for testing equality, noninferiority, superiority, and equivalence based on odds ratio were derived under both parallel and one-arm crossover designs. An example concerning the study of odds ratio between a test compound (treatment) and a standard therapy (control) for prevention of re...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120016231

    authors: Wang H,Chow SC,Li G

    更新日期:2002-11-01 00:00:00